Ensartinib Clinical Trials

4 actively recruiting trials

▼ -1 trial since August 2026

Also known as: X-396, X-396 capsule

Pipeline

Phase 2: 2Phase 1/2: 1

Top Sponsors

Sun Yat-sen University1
Peking Union Medical College Hospital1
Hebei Medical University Fourth Hospital1
Betta Pharmaceuticals Co., Ltd.1

Indications

Cancer4
Lung Cancer3
Ensartinib1
Anaplastic Lymphoma Kinase I1171N1
Solid Advanced Tumor1

Other4 trials

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Phase 2

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Phase 2

Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.